Participant flow

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant · Source last updated 2026-08-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Beginning between day 100-110, patients receive oral lenalidomide once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day.

   id

   FG000

   title

   Lenalidomide Maintenance

2. description

   Beginning between day 100-110, patients receive oral placebo once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day. (closed as of 12/17/09)

   id

   FG001

   title

   Placebo Maintenance

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         231

      2. group Id

         FG001

         num Subjects

         229

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         231

      2. group Id

         FG001

         num Subjects

         229

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

After registration, participants underwent a peripheral blood stem cell transplant. Of the 568 participants, 460 were randomized to either arm, stratified by beta2 microglobulin, prior thalidomide use and prior lenalidomide use. (108 participants dropped out prior to randomization, most common reasons include: progression, ineligible, refusal)

recruitment Details

From December 2004 and July 2009, a total of 568 participants were recruited to this study.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice